Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
09:32 ET | 483 | 3.61 |
09:36 ET | 600 | 3.88 |
09:41 ET | 200 | 3.735 |
09:43 ET | 334 | 3.6 |
10:33 ET | 100 | 3.51 |
10:39 ET | 600 | 3.565 |
11:58 ET | 155 | 3.565 |
12:21 ET | 1200 | 3.565 |
12:41 ET | 100 | 3.5921 |
12:50 ET | 450 | 3.6 |
12:57 ET | 345 | 3.59 |
01:10 ET | 138 | 3.64 |
01:33 ET | 521 | 3.67 |
02:02 ET | 100 | 3.68 |
02:24 ET | 100 | 3.67 |
02:33 ET | 400 | 3.7 |
03:07 ET | 3045 | 3.73 |
03:09 ET | 1284 | 3.75 |
03:14 ET | 115 | 3.765 |
03:16 ET | 800 | 3.7518 |
03:18 ET | 600 | 3.7609 |
03:45 ET | 702 | 3.74 |
03:56 ET | 125 | 3.735 |
03:59 ET | 3941 | 3.77 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 211.5M | -2.0x | --- |
Invivyd Inc | 219.5M | -0.9x | --- |
Ovid Therapeutics Inc | 217.1M | -4.3x | --- |
Elevation Oncology Inc | 219.6M | -3.6x | --- |
Renovaro Inc | 219.8M | -1.9x | --- |
Boundless Bio Inc | 203.0M | 0.0x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $211.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.55 |
EPS | $-1.88 |
Book Value | $4.32 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.